ClinicalTrials.gg
Status unknownNCT04366206Updated Apr 28, 2020

Factors Associated With Clinical Outcomes in Patients Hospitalized for Covid-19 in GHT-93 Est

An observational study in COVID and SARS-CoV 2, sponsored by Centre Hospitalier Intercommunal Robert Ballanger. Status unknown at 2 sites in France. Per ClinicalTrials.gov, last updated 2020-04-28.

Sponsored by Centre Hospitalier Intercommunal Robert Ballanger · Observational

How we know

The sponsor has not verified this record recently (last verified Apr 2020), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
143
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 782 studies in COVID-19 with a site in France — 51 open to participants now, 68 under way, 7 of them phase 3. COVID-19 · France.

Planned enrollment
314th of 486
143 · median 298
Started
2020
with 498 others
Observational
486 of 782
27 open now
Registered
107th of 782
by date

Among the 782 studies in COVID-19 with a site in France, this one is the 314th largest by planned enrollment of the 486 observational ones that give a count, is one of 499 that started in 2020, is one of 486 observational ones, and was the 107th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

51 of the 782 studies in COVID-19 with a site in France are open now. Recruiting first, the newest first:

46 more — sign in →

All 51 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 782 studies in COVID-19 with a site in France, or all of them as a file.
02

Study summary

Healthcare centers treated several hundreds of patients with Covid-19 and prospectively gathered information in electronic format between March, 2020 to April, 2020. In the course of Covid-19 treatment, physicians employed several drugs, including hydroxychloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, baricitinib, sarilumab, corticosteroids and systematic antibiotics (list is not exhaustive).

This cohort study aims to assess factors associated with clinical outcomes in patients hospitalized for Covid-19, by analyzing associations between treatments and outcomes.

All data are collected in electronical records during routine practice.

Read the detailed description

Healthcare centers treated several hundreds of patients with Covid-19 and prospectively gathered information in electronic format between March, 2020 to April, 2020. In the course of Covid-19 treatment, physicians employed several drugs, including hydroxychloroquine, azithromycin, lopinavir/ritonavir, tocilizumab, baricitinib, sarilumab, corticosteroids and systematic antibiotics (list is not exhaustive).

This cohort study aims to assess factors associated with clinical outcomes in patients hospitalized for Covid-19.

Risk factors which will be studied include: baseline characteristics such as medical history and drugs with corresponding administration protocols.

Main outcomes include all-cause mortality, need for mechanical ventilation, for ICU transfer and all relevant biological syndromes.

All data are collected in electronical records during routine practice and additional data may be collected retrospectively.

03

Conditions studied

  • COVID
  • SARS-CoV 2

Browse trials for

Keywords

  • covid-19
  • SARS-Cov-2
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients hospitalized for Covid-19 may be eligible to join this cohort study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • hospitalized for Covid-19
  • severe pneumonia defined as pulse O2 \< 96% despite > 6L/min

Exclusion criteria

Exclusion Criteria:

  • lack of consent
  • palliative care patients
  • patients in ICU
  • patients transferred from ICU
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
143 participants (estimated)
Target follow-up
14 Weeks
Patient registry
Yes

Groups and cohorts

  • Patients exposed to the study variable

    Depending on the studied variable (treatment or risk factor)

  • Patients not exposed to the study variable

    Depending on the studied variable (treatment or risk factor)

06

What researchers measure

Primary outcomes

  1. Composite of death and mechanical ventilation

    Composite of death and mechanical ventilation

    Time frame: At 14-days follow-up

Secondary outcomes

  1. Need for mechanical ventilation

    Need for mechanical ventilation

    Time frame: At 14-days follow-up

  2. Death

    All-cause mortality

    Time frame: At 14-days follow-up

  3. Acute kidney injury

    As defined by AKIN

    Time frame: At 14-days follow-up

  4. Acute respiratory distress syndrome

    As defined by Berlin criteria: P/F ratio below 200, with PEEP \> +5 cmH20, radiologic findings compatible with ARDS and not explained by heart failure, occurring within 7 days of an acute pulmonary or non-pulmonary aggression.

    Time frame: At 14-days follow-up

  5. Cardiac arrhythmia and conduction disorder

    Documented by EKG monitoring

    Time frame: At 14-days follow-up

  6. Composite of death and mechanical ventilation

    Composite of death and mechanical ventilation

    Time frame: Up to 60 days after inclusion

  7. 60-days mortality

    All cause mortality at 60 days follow-up whenever possible

    Time frame: Up to 60 days after inclusion

  8. 60-days mechanical ventilation

    If patient was mechanically ventilated within 60 days of inclusion

    Time frame: Up to 60 days after inclusion

07

Study locations

1 of 2 sites recruiting
  • Centre Hospitalier Intercommunal Robert Ballanger
    Aulnay-sous-Bois, 93600, France
    Recruiting
  • Groupe Hospitalier Pitie Salpetriere
    Paris, 75013, France
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2020 (actual). Primary completion is estimated for Jul 2020, 4 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 4 months is below that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2020
First posted
Apr 28, 2020
StartActual
Mar 14, 2020
Primary completionEst.
Jul 31, 2020
CompletionEst.
Jul 31, 2020
Last update
Apr 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04366206
Lead sponsor
Centre Hospitalier Intercommunal Robert Ballanger
Collaborators
Groupe Hospitalier Pitie-Salpetriere
Responsible party
Dr. Hélène GROS (Principal Investigator, Centre Hospitalier Intercommunal Robert Ballanger) — Principal investigator
First posted
Apr 28, 2020
Start date
Mar 14, 2020
Primary completion
Jul 31, 2020 (estimated)
Completion
Jul 31, 2020 (estimated)
Last update
Apr 28, 2020

Study contacts

Hélène Gros, MD
Contact
helene.gros@ght-gpne.fr
01 49 36 73 67 ext. +33
Hélène Gros, MD
study director · Robert Ballanger

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion